<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29387128</article-id><article-id pub-id-type="pmc">5745661</article-id><article-id pub-id-type="doi">10.1155/2017/4363716</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A Herbal Medicine,<italic> Gongjindan</italic>, in Subjects with Chronic Dizziness (GOODNESS Study): Study Protocol for a Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial for Effectiveness, Safety, and Cost-Effectiveness</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6160-0339</contrib-id><name><surname>Shin</surname><given-names>Seungwon</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jinyoung</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0624-3671</contrib-id><name><surname>Yu</surname><given-names>Ami</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2410-4704</contrib-id><name><surname>Seo</surname><given-names>Hyung-Sik</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8940-7867</contrib-id><name><surname>Shin</surname><given-names>Mi-Ran</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Jae-Heung</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0356-9433</contrib-id><name><surname>Yi</surname><given-names>Gilhee</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6228-3312</contrib-id><name><surname>Hong</surname><given-names>Seung-Ug</given-names></name><email>heenthsu@hanmail.net</email><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3860-0533</contrib-id><name><surname>Lee</surname><given-names>Euiju</given-names></name><email>sasangin@daum.net</email><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea</aff><aff id="I2">
<sup>2</sup>Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine Hospital, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea</aff><aff id="I3">
<sup>3</sup>Department of Korean Medical Ophthalmology &#x00026; Otolaryngology &#x00026; Dermatology, School of Korean Medicine, Pusan National University, 20 Geumo-ro, Mulgeum-eup, Yangsan, Gyeongsangnam-do 50612, Republic of Korea</aff><aff id="I4">
<sup>4</sup>Department of Sasang Constitutional Medicine, College of Oriental Medicine, Semyung University, 65 Semyung-ro, Jecheon, Chungcheongbuk-do 27136, Republic of Korea</aff><aff id="I5">
<sup>5</sup>Department of Korean Rehabilitation Medicine, College of Korean Medicine, Kyung Hee University, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea</aff><aff id="I6">
<sup>6</sup>Department of Oriental Medicine Ophthalmology &#x00026; Otolaryngology &#x00026; Dermatology, College of Oriental Medicine, Dongguk University, 27 Dongguk-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10326, Republic of Korea</aff><aff id="I7">
<sup>7</sup>Department of Sasang Constitutional Medicine, College of Korean Medicine, Kyung Hee University, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea</aff><author-notes><fn fn-type="other"><p>Academic Editor: Carmen Mannucci</p></fn></author-notes><pub-date pub-type="ppub"><year>2017</year></pub-date><pub-date pub-type="epub"><day>13</day><month>12</month><year>2017</year></pub-date><volume>2017</volume><elocation-id>4363716</elocation-id><history><date date-type="received"><day>16</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Seungwon Shin et al.</copyright-statement><copyright-year>2017</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>This study protocol aims to explore the effectiveness, safety, and cost-effectiveness of a herbal medication,<italic> Gongjindan</italic> (GJD), in patients with chronic dizziness. This will be a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, clinical trial. Seventy-eight patients diagnosed with Meniere's disease, psychogenic dizziness, or dizziness of unknown cause will be randomized and allocated to either a GJD or a placebo group in a 1&#x02009;:&#x02009;1 ratio. Participants will be orally given 3.75&#x02009;g GJD or placebo in pill form once a day for 56 days. The primary outcome measure will be the Dizziness Handicap Inventory score. Secondary outcome measures will be as follows: severity (mean vertigo scale and visual analogue scale) and frequency of dizziness, balance function (Berg Balance Scale), fatigue (Fatigue Severity Scale) and deficiency pattern/syndrome (qi blood yin yang-deficiency questionnaire) levels, and depression (Korean version of Beck's Depression Inventory) and anxiety (State-Trait Anxiety Inventory) levels. To assess safety, adverse events, including laboratory test results, will be monitored. Further, the incremental cost-effectiveness ratio will be calculated based on quality-adjusted life years (from the EuroQoL five dimensions' questionnaire) and medical expenses. Data will be statistically analyzed at a significance level of 0.05 (two-sided). This trial is registered with ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03219515">NCT03219515</ext-link>, in July 2017.</p></abstract><funding-group><award-group><funding-source>Ministry of Health and Welfare</funding-source><award-id>HB16C0010</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Dizziness is a typical manifestation of various neurological diseases. It is mostly related to vestibular disorders of the inner ear, such as benign paroxysmal positional vertigo (BPPV), vestibular neuritis, or Meniere's disease (MD) [<xref rid="B1" ref-type="bibr">1</xref>]. However, the symptom may also arise from some conditions involving the central nervous system (e.g., cerebral stroke, vertebrobasilar insufficiency), cardiovascular diseases (e.g., arrhythmia, orthostatic hypotension) [<xref rid="B2" ref-type="bibr">2</xref>], or even certain psychiatric conditions [<xref rid="B3" ref-type="bibr">3</xref>]. In some cases, chronic and recurrent dizziness fails to receive a diagnosis and remains as unspecified or undefined dizziness in clinical records.</p><p>According to studies investigating the etiology of recurrent dizziness, 12.5% of cases were attributed to MD [<xref rid="B4" ref-type="bibr">4</xref>], 15% to psychogenic dizziness [<xref rid="B5" ref-type="bibr">5</xref>], and 10&#x02013;52% to dizziness of unknown cause [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. Public healthcare data systems also show the incidence of dizziness has increased by approximately 20% in the past 5 years [<xref rid="B7" ref-type="bibr">7</xref>].</p><p>Otorhinolaryngologists prescribe vasodilators or diuretics to patients with MD. For example, betahistine is frequently used as a full agonist of the H1 receptors located in blood vessels in the inner ear, which can increase local vasodilation and help alleviate symptoms [<xref rid="B8" ref-type="bibr">8</xref>]. Moreover, diuretics are sometimes used to treat endolymphatic hydrops. However, there is no confirmatory evidence of the utility of these treatments [<xref rid="B4" ref-type="bibr">4</xref>]. For psychogenic dizziness, psychiatrists administer to patients antianxiety agents or antidepressants, accompanied by cognitive-behavioral therapy [<xref rid="B3" ref-type="bibr">3</xref>], which also lack clinical verification. If the dizziness is due to unknown causes, drugs, such as meclizine, clonazepam, or lorazepam, or rehabilitation therapy is prescribed, which mostly rely on anecdotal evidence [<xref rid="B6" ref-type="bibr">6</xref>].</p><p>Due to these limitations, many patients with dizziness visit practitioners of traditional medicine in Korea. Traditional Korean Medicine (TKM) doctors prescribe various herbal medications to these patients, based on syndrome/pattern identification [<xref rid="B9" ref-type="bibr">9</xref>].<italic> Gongjindan</italic> (GJD) is one of the most preferred options. A classic Korean book of traditional medicine,<italic> Dongeuibogam</italic>, suggests that GJD can be prescribed for liver-deficiency syndrome/pattern with symptoms of dizziness/vertigo, dim eyes, a pale face, and/or weak muscles [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. However, the modern scientific level of the evidence for GJD remains low.</p><p>Most studies have been<italic> in vivo</italic> or<italic> in vitro</italic> experiments that have demonstrated the efficacy of GJD in ameliorating memory impairments [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>] or fatigue [<xref rid="B14" ref-type="bibr">14</xref>], its antioxidant effects [<xref rid="B15" ref-type="bibr">15</xref>], neuroregulatory effects for transient middle cerebral artery occlusion [<xref rid="B16" ref-type="bibr">16</xref>] or Alzheimer's disease [<xref rid="B17" ref-type="bibr">17</xref>], and lipid-lowering effect in hyperlipidemia [<xref rid="B18" ref-type="bibr">18</xref>]. Clinical studies have been rarer. A retrospective study for Alzheimer's disease [<xref rid="B19" ref-type="bibr">19</xref>] and a case report for dizziness of patients with anemia [<xref rid="B20" ref-type="bibr">20</xref>] have been published. Only one randomized controlled trial (RCT) with GJD has so far been planned with fatigue patients [<xref rid="B21" ref-type="bibr">21</xref>], which has not announced its results yet. Therefore, the effectiveness of GJD should be explored clinically with qualified RCTs using a placebo for comparison. This study would be the first RCT for chronic dizziness to explore the clinical effectiveness, safety, and cost-effectiveness of a herbal drug, GJD pills.</p><p>This study protocol is primarily aimed at exploring the effectiveness of GJD in patients with chronic dizziness, compared to placebo. Additionally, the safety and cost-effectiveness of GJD will be investigated.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><p>This study protocol has been designed to conform with Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT), 2013 statement [<xref rid="B22" ref-type="bibr">22</xref>], and the elaborated Consolidated Standards of Reporting Trials (CONSORT) statement for herbal interventions [<xref rid="B23" ref-type="bibr">23</xref>].</p><sec id="sec2.1"><title>2.1. Objectives and Hypothesis</title><p>The primary objective of this study is to evaluate the effect of GJD administration for 8 weeks, compared to placebo, on chronic dizziness (MD, psychogenic dizziness, or dizziness of unknown cause). The alternative hypothesis is that the mean difference between Dizziness Handicap Inventory (DHI) scores at baseline and endpoint in the GJD group will not be equal to that in the placebo group.</p><p>Additionally, the changes in dizziness severity and frequency will be evaluated with validated scales. Further, the levels of fatigue, depression, anxiety, and quality of life (QoL) will be compared between the two groups posttreatment. The safety of GJD administration will be examined based on laboratory tests and adverse events (AEs). Finally, the cost-effectiveness of GJD will be evaluated with quality-adjusted life years (QALY).</p></sec><sec id="sec2.2"><title>2.2. Study Design</title><p>This study will be a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, clinical trial. Seventy-eight patients diagnosed with MD, psychogenic dizziness, or dizziness of unknown cause, with a DHI score &#x02265; 24 at baseline, and having complained of dizziness for more than 1 month will be randomized and allocated to either the GJD or placebo group in a 1&#x02009;:&#x02009;1 ratio. They will be orally given 3.75&#x02009;g GJD or placebo in pill form once a day for 8 weeks (56 pills in total). To collect data for the cost-effectiveness analysis, we will follow up the patients for up to 12 months from randomization. The study flowchart is displayed in diagram form in <xref ref-type="fig" rid="fig1">Figure 1</xref> and the specified timetable is presented in <xref ref-type="table" rid="tab1">Table 1</xref>.</p></sec><sec id="sec2.3"><title>2.3. Setting and Recruitment</title><p>Four TKM hospitals in the Republic of Korea, that is, Kyung Hee University Korean Medicine Hospital in Seoul, Dongguk University Ilsan Oriental Hospital in Goyang (Gyeonggi-do), Pusan National University Korean Medicine Hospital in Yangsan (Gyeongsangnam-do), and Semyung University Korean Medicine Hospital in Chungju (Chungcheongbuk-do), will enroll eligible participants. Participants will be recruited mostly from the respective outpatient clinics. Moreover, study advertisements will be posted on webpages and notice boards.</p></sec><sec id="sec2.4"><title>2.4. Ethical Review and Trial Registration</title><p>This protocol (version 2.5) and the informed consent forms have been peer-reviewed and approved by the Institutional Review Board of Kyung Hee University Korean Medicine Hospital (approval number KOMCIRB-170417-HRBR-012) following the scientific content and ethical compliance with regulations, that is, Good Clinical Practice and relevant laws by Ministry of Food and Drug Safety in Korea. The study has been registered at ClinicalTrials.gov in July 2017 (identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03219515">NCT03219515</ext-link>).</p></sec><sec id="sec2.5"><title>2.5. Eligibility Criteria</title><p>Participants will be included if they satisfy all of the following criteria:<list list-type="order"><list-item><p>Age between 20 and 79 years, of either sex</p></list-item><list-item><p>Dizziness originating from MD, psychogenic cause, or unknown cause</p></list-item><list-item><p>Recurring symptom of dizziness for more than 1 month</p></list-item><list-item><p>DHI score &#x02265; 24 at baseline</p></list-item><list-item><p>Liver-deficiency pattern/syndrome identified by TKM doctors</p></list-item><list-item><p>Willingness to provide written informed consent.</p></list-item></list></p><p>The targeted scope of chronic dizziness has been established based on a preceding acupuncture trial [<xref rid="B24" ref-type="bibr">24</xref>]. The liver-deficiency syndrome is defined as having all of the main symptoms and at least two of the secondary symptoms [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B25" ref-type="bibr">25</xref>]. The main symptoms include dizziness, dim eyes, and pale face. The secondary symptoms include lack or a momentary loss of vision, numbness at extremities, muscular spasm, twitching and/or cramping, hypochondriac pain, dry or pale fingernails, toenails, or lips, tinnitus, and scant menstruation. Two TKM doctors who have 1 year or more of clinical experience will independently identify the pattern/syndrome, and only the patients diagnosed with consistent liver-deficiency pattern/syndrome will be enrolled in the study.</p><p>Participants will be excluded if any of the following criteria is applicable:<list list-type="order"><list-item><p>Dizziness attributable to vestibular disorders (e.g., benign paroxysmal positional vertigo, peripheral vestibulopathy, labyrinthitis, and vestibular neuronitis)</p></list-item><list-item><p>Dizziness attributable to central nervous system (CNS) disorders (e.g., cerebellar ataxia, stroke, demyelination, vertebrobasilar insufficiency, seizure, increased intracranial pressure, Parkinson's disease, and migraines)</p></list-item><list-item><p>Cervicogenic dizziness</p></list-item><list-item><p>Dizziness attributable to cardiovascular disorders (e.g., arrhythmia, heart valvular disease, anemia, orthostatic hypotension, and coronary artery disease)</p></list-item><list-item><p>Any active or uncontrolled disease that might cause dizziness (e.g., uncontrolled diabetes mellitus, hypertension, and respiratory or endocrinological disorders)</p></list-item><list-item><p>Dizziness attributable to medication side effects</p></list-item><list-item><p>Severe chronic or terminal diseases (malignant cancer, tuberculosis, etc.)</p></list-item><list-item><p>Intake of antivertiginous drugs that cannot be discontinued</p></list-item><list-item><p>Following physiotherapy, manual therapy (e.g., vestibular rehabilitation), and/or cognitive-behavioral therapy for the treatment of dizziness</p></list-item><list-item><p>Aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), or creatinine &#x0003e; 3 &#x000d7; upper limit of normal range at baseline</p></list-item><list-item><p>Women of (suspected) pregnancy or breast-feeding</p></list-item><list-item><p>Allergic reactions to the study medications</p></list-item><list-item><p>Suspicion of alcohol and/or drug abuse</p></list-item><list-item><p>Enrollment in another clinical study presently or within 30 days prior to the initial administration of the study medications</p></list-item><list-item><p>Difficulty in reliably communicating with the investigators or likelihood of inability to follow instructions</p></list-item><list-item><p>Reasons for ineligibility of participation judged by investigators.</p></list-item></list></p></sec><sec id="sec2.6"><title>2.6. Dropout Criteria</title><p>Already enrolled participants will be dropped out if they withdraw their consent for participation, are lost to follow-up, cannot continue participation due to adverse events or complications, consume disallowed medications, or markedly deviate from the study protocol.</p></sec><sec id="sec2.7"><title>2.7. Randomization, Allocation, and Blinding</title><p>An independent statistician (A. Yu) will generate random sequence numbers via SAS&#x000ae; 9.4 software (SAS Institute Inc., Cary, NC). Stratified randomization will be performed in blocks in order to keep the sizes of both arms similar with the strata of the study sites. The random number table will be delivered from the statistician to a pharmaceutical company, where GJD and placebo pills will be produced.</p><p>The investigational products labeled with random codes will be provided to a pharmacist, who will dispense them to the enrolled participants. According to the order of enrollment, participants will be allocated to either the GJD group or the placebo group in a 1&#x02009;:&#x02009;1 ratio. As only the statistician and the pharmaceutical company will have access to the random table throughout the study, allocation will stay concealed.</p><p>Since we are going to use placebo pills that look, taste, and smell similar to GJD pills, both investigators and patients will stay blinded until the completion of the study. Only clinical emergency due to serious AEs will break the code and blinding.</p></sec><sec id="sec2.8"><title>2.8. <italic>Gongjindan</italic> (GJD)</title><p>The GJD group will be orally given 3.75&#x02009;g of GJD in pill form (product name: Iksu Gongjindan), on an empty stomach every morning for 8 weeks (56 days). This has been determined based on clinical experience within the dose regimen (1 to 3 oral administrations per day) of GJD pills approved by the Ministry of Food and Drug Safety in Korea. The manufacturer, Iksu Pharmaceutical Co. Ltd. (Gwangju, Republic of Korea). obtained Good Manufacturing Practice authorization from the Ministry of Food and Drug Safety in Korea. The GJD pill and its ingredients have also been registered with the same governmental authority.</p><p>GJD is composed of six herbs (with country of origin and material standard; KHP, Korean Herbal Pharmacopoeia; KP, Korean Pharmacopoeia): Cervi Parvum (<italic>Cervus elaphus</italic> Linn&#x000e9;, family Cervidae, Russia, KHP) 444.33&#x02009;mg, Angelica Gigas Root (<italic>Angelica gigas</italic> Nakai, family Umbelliferae, Korea, KP) 444.33&#x02009;mg, Cornus Fruit (<italic>Cornus officinalis</italic> Siebold et Zuccarini, family Cornaceae, China, KP) 444.33&#x02009;mg, Ginseng (<italic>Panax ginseng</italic> C. A. Meyer, family Araliaceae, Korea, KP) 444.33&#x02009;mg, Steamed Rehmannia Root (<italic>Rehmannia glutinosa</italic> Liboschitz ex Steudel, family Scrophulariaceae, China, KP) 444.33&#x02009;mg, and Musk (<italic>Moschus moschiferus</italic> Linn&#x000e9;, family Moschidae, Russia, KHP) 74&#x02009;mg.</p><p>After the herbs are weighed, they are pulverized, sterilized, and mixed with the excipient (corn starch 233.33&#x02009;mg), binders (glycerin 550&#x02009;mg and suitable amount of honey), and preservative (sodium benzoate 2.25&#x02009;mg). The mixture is formed into a pill (3.75&#x02009;g/pill) and covered with gilt paper. Separately packaged and labeled GJD will be directly delivered to the pharmacists of each study site from the pharmaceutical company. A voucher specimen will be retained and kept with the manufacturer.</p></sec><sec id="sec2.9"><title>2.9. Placebo</title><p>Since there have been no clinical trials to show the effectiveness and/or safety of GJD pills over placebo, we have decided to adopt placebo control for this dizziness trial. Placebo pills will be made by the same pharmaceutical company as the GJD pills. They will be made similar in appearance, taste, and odor to the GJD pills, containing excipients (corn starch 997.76&#x02009;mg, sodium carboxymethyl cellulose 80&#x02009;mg, lactose hydrate 1.402&#x02009;mg, and citric acid hydrate 40&#x02009;mg), coloring agents (sepia color 10&#x02009;mg and caramel color 300&#x02009;mg), binders (glycerin 300&#x02009;mg and honey 400&#x02009;mg), flavoring agents, and preservative (sodium benzoate 2.24&#x02009;mg) with gilt-paper covering. The entire manufacturing process will follow the relevant guidelines of the Korean Ministry of Food and Drug Safety.</p><p>The placebo group will be orally given 3.75&#x02009;g of placebo pill on an empty stomach every morning for 8 weeks (56 days).</p></sec><sec id="sec2.10"><title>2.10. Concomitant Medications</title><p>All of the concomitant medications will be recorded throughout the trial. No other drugs (betahistine, difenidol, flunarizine, cinnarizine, dimenhydrinate, gingko, meclizine, metoclopramide, scopolamine, pentoxifylline, perphenazine, ergoloid mesylate, droperidol, phenobarbital, prochlorperazine, promethazine, trimethobenzamide, or vertigoheel, etc.) or herbal drugs to manage the symptom of dizziness will not be allowed. Moreover, other therapies for dizziness, like physical therapy, rehabilitation, acupuncture, electroacupuncture, pharmacoacupuncture, moxibustion, cupping, and cognitive-behavioral therapies, will be disallowed during the study.</p><p>The following drugs, which can induce drug-related dizziness, will be closely monitored: <italic>&#x003b1;</italic>1-adrenergic antagonists, alcohol, aminoglycosides, anticonvulsants, antidepressants, anti-Parkinson medication, antipsychotics, <italic>&#x003b2;</italic>-blockers, calcium channel blockers, class 1a antiarrhythmics, digitalis glycosides, diuretics, narcotics, oral sulfonylurea, vasodilators, anticoagulants, antidementia agents, antihistamines (sedating), antirheumatic agents, anti-infectives (anti-influenza agents, oral antifungals, quinolones), antithyroid agents, anxiolytics, attention-deficit/hyperactivity disorder agents, cholesterol-lowering agents, bronchodilators, skeletal muscle relaxants, urinary and gastrointestinal antispasmodics, and so on.</p></sec><sec id="sec2.11"><title>2.11. Screening Process</title><p>After a TKM doctor obtains informed consent from a patient, he/she will go through an extensive screening process for the eligibility decision. Height, weight, body mass index, vital signs (blood pressure, pulse, and body temperature), and electrocardiogram will be measured. Furthermore, blood and urine laboratory tests will be performed, including pregnancy testing. History of medical diseases and drugs will be recorded. If the patient was under administration of any of the drugs disallowed in this study, he/she will be able to participate after a 2-week wash-out period. To rule out untargeted diseases related to chronic dizziness, as listed in the exclusion criteria, we are going to test for CNS abnormalities (deep tendon reflex, Hoffman sign, Babinski sign, ankle clonus, finger to nose, finger to finger, rapid alternating movement, heel to shin, Romberg's test, Brudzinski sign, Kernig sign, Naffziger test, etc.). Additionally, spontaneous, gaze-evoked, positional, and positioning (Dix-Hallpike) nystagmus will be tested for, too. Finally, two TKM doctors will judge if the patient has liver-deficiency pattern/syndrome or not, and those that will receive a consistent diagnosis will be considered to be eligible. The whole process is depicted in <xref ref-type="table" rid="tab1">Table 1</xref>.</p></sec><sec id="sec2.12"><title>2.12. Outcomes</title><sec id="sec2.12.1"><title>2.12.1. Primary Outcome</title><p>
<italic>Dizziness Handicap Inventory (DHI)</italic>. DHI was developed to evaluate functional, emotional, and physical impairments due to dizziness [<xref rid="B26" ref-type="bibr">26</xref>]. This widely used scale for patients with dizziness is a patient-rated outcome (PRO) and has been validated in Korean [<xref rid="B27" ref-type="bibr">27</xref>]. The scale consists of 25 items (0, 2, or 4 scores/item, 0&#x02013;100 scores). The primary endpoint is the mean difference of DHI total score between the baseline and the endpoint of the treatment period. Secondarily, the before-and-after effect of GJD between the baseline and every visit will also be investigated.</p></sec><sec id="sec2.12.2"><title>2.12.2. Secondary Outcomes</title><p>The following outcomes will be evaluated at baseline, mid-term point, and the endpoint of the treatment. The mean differences of each scale score from the baseline and each measurement point will be compared between the GJD and the placebo groups.</p><p>
<italic>Mean Vertigo Score (MVS)</italic>. MVS is a PRO assessing the intensity of dizziness and has been employed in various clinical trials [<xref rid="B28" ref-type="bibr">28</xref>&#x02013;<xref rid="B35" ref-type="bibr">35</xref>]. It includes six items for symptom types and six items for symptom provoking conditions. Patients answer on a scale from 0 (none) to 4 (very strong) and the final score is calculated as the sum divided by 12 (0&#x02013;4 scores).</p><p>
<italic>Visual Analogue Scale (VAS)</italic>. The VAS was used in the previous studies on dizziness [<xref rid="B36" ref-type="bibr">36</xref>&#x02013;<xref rid="B41" ref-type="bibr">41</xref>]. This scale consists of a 10&#x02009;cm line, where 0 represents &#x0201c;not dizzy at all&#x0201d; and 10 &#x0201c;dizziest I can imagine being.&#x0201d;</p><p>
<italic>Dizziness Frequency</italic>. Patients will be asked how many episodes of dizziness they experience. The frequency will be scored as 0 (none), 1 (less than once a month), 2 (1&#x02013;4 episodes/month), 3 (1&#x02013;4 episodes/week), 4 (once a day), or 5 (more than twice a day), as per the notation used in the previous studies [<xref rid="B38" ref-type="bibr">38</xref>&#x02013;<xref rid="B41" ref-type="bibr">41</xref>].</p><p>
<italic>Berg Balance Scale (BBS)</italic>. The BBS was originally developed for elderly patients with balance impairment; however, it has been used to assess overall balance ability regardless of age. Its reliability [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>], validity [<xref rid="B44" ref-type="bibr">44</xref>], and sensitivity [<xref rid="B45" ref-type="bibr">45</xref>] have been verified and it has been validated in Korean [<xref rid="B46" ref-type="bibr">46</xref>]. Patients will be asked to perform 14 tasks and each task will be evaluated separately.</p><p>
<italic>Fatigue Severity Scale (FSS)</italic>. GJD is widely administered to patients with chronic fatigue. In this study, we are going to assess the patients' fatigue level with the FSS. This 7-point Likert scale (nine items, 9&#x02013;63 score range) is a PRO and it has been validated [<xref rid="B47" ref-type="bibr">47</xref>].</p><p>
<italic>Global Perceived Effect (GPE)</italic>. GPE is a validated scale evaluating a patient's perception of symptom worsening or improvement around a specific timepoint [<xref rid="B48" ref-type="bibr">48</xref>]. This scale has also been used in clinical studies on dizziness [<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>], and it consists of seven options (1 for completely recovered to 7 for worst ever).</p><p>Based on the previous study showing that the patients with dizziness can become markedly depressed and anxious [<xref rid="B49" ref-type="bibr">49</xref>], the following scales will also be included.</p><p>
<italic>Korean Version of Beck's Depression Inventory (K-BDI)</italic>. The K-BDI is a PRO evaluating the severity of depression with 21 items (0 to 3/points, 63 points in total). The Korean version of this scale has been validated [<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>].</p><p>
<italic>State-Trait Anxiety Inventory (STAI)</italic>. The STAI assesses the level of anxiety in the subdomains of state and trait. Each subdomain includes 20 items and each item has the options of 1&#x02013;4 points (20&#x02013;80 scores/subdomain). Its reliability and validity have been shown [<xref rid="B52" ref-type="bibr">52</xref>].</p><p>
<italic>Qi Blood Yin Yang-Deficiency Questionnaire (QBYY-Q)</italic>. GJD is a herbal medication prescribed to patients with liver-deficiency pattern/syndrome in TKM. Therefore, we assumed that the level of deficiency pattern/syndrome could vary between groups at the end of the intervention. QBYY-Q is a PRO to evaluate the severity of qi-, blood-, yin-, and yang-deficiency pattern/syndrome [<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>]. A previous clinical study on chronic fatigue demonstrated the reliability and validity of this scale [<xref rid="B55" ref-type="bibr">55</xref>]. The scale consists of 32 items and each item is rated from 0 to 3 points.</p></sec><sec id="sec2.12.3"><title>2.12.3. Blinding Assessment</title><p>This is a double-blind clinical trial with placebo control. Both study participants and TKM doctors will remain blind until the end of the trial. At the end of treatment of each participant, they will be asked in which group they think they belonged to, the GJD group, placebo group, or unknown, and the new Blinding Index (BI) will be calculated following [<xref rid="B56" ref-type="bibr">56</xref>]. The index score varies within 1 (complete lack of blinding), 0 (consistent with perfect blinding), or &#x02212;1 (guessed they were in the opposite group).</p></sec><sec id="sec2.12.4"><title>2.12.4. Safety Assessment</title><p>The AEs will be monitored during the whole treatment period. The following adverse reactions are expected: anorexia, discomfort feeling of stomach area, nausea, vomiting, diarrhea, or rash on skins. The intensity and frequency of each episode will be recorded. Moreover, laboratory tests will be performed at baseline and the endpoint. Complete blood cell tests (red blood cell, hemoglobin, hematocrit, platelet, and white blood cell), serum biochemical tests (creatinine, BUN, ALT, AST, and glucose), and urinalysis (pH, specific gravity, glucose, ketone, red blood cell, nitrate, total protein, bilirubin, urobilinogen, and white blood cell) will be performed. If serious AEs occur, postmanagement will be properly conducted.</p></sec><sec id="sec2.12.5"><title>2.12.5. Cost-Effectiveness Assessment</title><p>The EuroQoL five dimensions' questionnaire (EQ-5D), consisting of two parts, that is, EQ-5D-5L and EQ VAS, will be used to assess quality of life, based on which QALY will be calculated. The Korean version of EQ-5D scale has been studied on its validity and reliability [<xref rid="B57" ref-type="bibr">57</xref>]. Also, direct costs (medical and nonmedical expenses) incurred in treating dizziness during the treatment (8 weeks) and follow-up (up to 12 months from randomization) periods will be investigated (<xref ref-type="table" rid="tab1">Table 1</xref>). Medical fee signifies the cost paid in hospitals or clinics. Nonmedical fee signifies transportation and time costs that patients would incur for dizziness treatment. Based on the calculated QALY and fees, the incremental cost-effectiveness ratio (ICER) will be estimated (ICER = &#x00394;&#x02009;&#x02009;cost/&#x00394; effectiveness). The ICER signifies the amount of cost necessary to improve by 1 unit of effectiveness.</p></sec></sec><sec id="sec2.13"><title>2.13. Sample Size Calculation</title><p>To calculate the effect size, we used a preceding RCT on acupuncture therapy for MD with DHI assessment, as there have been no clinical studies for GJD effectiveness in chronic dizziness [<xref rid="B58" ref-type="bibr">58</xref>]. The null hypothesis is that <italic>&#x003bc;</italic><sub>GJD</sub> = <italic>&#x003bc;</italic><sub>placebo</sub>, while the alternative hypothesis is <italic>&#x003bc;</italic><sub>GJD</sub> &#x02260; <italic>&#x003bc;</italic><sub>placebo</sub>, where <italic>&#x003bc;</italic> denotes the mean difference of DHI score between the baseline and endpoint. With the mean difference (&#x02212;3.63) and the standard deviation (4.84), under the assumption of correlation coefficient (0.1), the sample size was calculated as 29 per group (two-sided, <italic>&#x003b1;</italic> = 0.05 and 1 &#x02212; <italic>&#x003b2;</italic> = 0.8). Therefore, we are going to recruit 78 participants for both groups (39 per group) under a 25% anticipated dropout rate.</p></sec><sec id="sec2.14"><title>2.14. Statistical Analysis</title><p>The primary and secondary variables for the effect assessments will be statistically analyzed by analysis of covariance (ANCOVA) or rank ANCOVA with group and site as covariates. If any demographic characteristics show significant difference between groups, those variables will also be used as covariates. When there is a significant interaction between diagnosis (MD, psychogenic dizziness, or dizziness of unknown cause) and group, subgroup analysis will be performed.</p><p>The confidence interval (CI) of BI will be addressed and blinding will be deemed successful when the CI includes the zero value. For safety assessment, the chi-squared test or Fisher's exact test will be performed with the proportions of AEs, while lab results will be compared between groups by chi-squared test (proportions of abnormal results) or McNemar's test (before-and-after comparison within a group). An independent statistician (A. Yu) will analyze any data with a significance level of 0.05 (two-sided) with SAS 9.4 software (SAS Institute Inc.).</p><p>The primary analysis will be performed with the full analysis set, which is defined as the group of participants who were prescribed at least once or more the GJD or placebo pills and for whom DHI was evaluated more than once. The missing data will be imputed with the last observation carried forward method. The per protocol set will be additionally analyzed, which includes only the participants who complete all the scheduled visits. We are going to include any participants who took at least one pill of the study drugs for the safety assessment.</p></sec></sec><sec id="sec3"><title>3. Results and Discussion</title><p>This study is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, clinical trial to explore the effectiveness, safety, and cost-effectiveness of a herbal drug, GJD, for patients with chronic dizziness attributable to MD, psychogenic dizziness, or dizziness of unknown cause. We are going to administer to patients GJD or placebo pills for 8 weeks and follow them up for 12 months. Four TKM hospitals in Korea will enroll 78 participants.</p><p>Dizziness may ensue from a variety of central or peripheral diseases and in some cases as a drug complication. This may complicate the diagnostic process. This study will include patients diagnosed with MD, psychogenic dizziness, or dizziness of unknown cause, which may create an issue with homogeneity. However, there were previous clinical studies which also focused on the symptom of dizziness with varied origin to demonstrate new efficacy [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B35" ref-type="bibr">35</xref>], including an acupuncture study for chronic dizziness [<xref rid="B24" ref-type="bibr">24</xref>], which has meaningfully been referred for this trial.</p><p>GJD is a widely prescribed herbal pill in Korea, but it is mostly used for patients with severe deficiency pattern/syndrome, especially those complaining of marked fatigue [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. However, based on the seminal work<italic> Dongeuibogam</italic> [<xref rid="B10" ref-type="bibr">10</xref>], we expect GJD to also manage chronic dizziness.</p><p>This RCT included various diseases (MD, psychogenic dizziness, or dizziness of unknown cause) inducing dizziness, which might reduce the level of homogeneity of patient population. The investigators discussed this issue, which might affect significantly the study results in the future. However, it was taken into consideration that this trial should reflex the real clinical practices as much as possible, which means that GJD is a herbal drug and it has been described based on pattern/syndrome identification in TKM. So, we think the screening process is one of the key parts for this trial to include eligible participants. Investigators and coordinators should be trained with written standard operating procedures for the trial before enrolling the first participants, since this study is a multicenter trial, to control the high quality throughout the whole process. Also, an independent monitor will regularly visit all the hospitals for auditing ethical and scientific issues.</p></sec><sec id="sec4"><title>4. Conclusions</title><p>We are going to conduct a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, clinical trial on patients with chronic dizziness to evaluate the effectiveness, safety, and cost-effectiveness of a herbal drug, GJD. This study has been approved by an ethics committee and registered in the WHO international clinical trials registry platform (CRIS), in the Republic of Korea.</p></sec></body><back><ack><title>Acknowledgments</title><p>This research is supported by the Korea Health Technology R&#x00026;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &#x00026; Welfare, Republic of Korea (Grant no. HB16C0010).</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>AST:</term><def><p>Aspartate aminotransferase</p></def></def-item><def-item><term>AE:</term><def><p>Adverse event</p></def></def-item><def-item><term>ALT:</term><def><p>Alanine aminotransferase</p></def></def-item><def-item><term>ANCOVA:</term><def><p>Analysis of covariance</p></def></def-item><def-item><term>BBS:</term><def><p>Berg Balance Scale</p></def></def-item><def-item><term>BI:</term><def><p>Blinding Index</p></def></def-item><def-item><term>BPPV:</term><def><p>Benign paroxysmal positional vertigo</p></def></def-item><def-item><term>BUN:</term><def><p>Blood urea nitrogen</p></def></def-item><def-item><term>CI:</term><def><p>Confidence interval</p></def></def-item><def-item><term>CONSORT:</term><def><p>Consolidated Standards of Reporting Trials</p></def></def-item><def-item><term>CRIS:</term><def><p>Clinical Research Information Service</p></def></def-item><def-item><term>DHI:</term><def><p>Dizziness Handicap Inventory</p></def></def-item><def-item><term>e:</term><def><p>Central nervous system</p></def></def-item><def-item><term>EQ-5D:</term><def><p>EuroQoL five dimensions' questionnaire</p></def></def-item><def-item><term>FSS:</term><def><p>Fatigue Severity Scale</p></def></def-item><def-item><term>GJD:</term><def><p>
<italic> Gongjindan</italic>
</p></def></def-item><def-item><term>GPE:</term><def><p>Global perceived effect</p></def></def-item><def-item><term>K-BDI:</term><def><p>Korean version of the Beck's Depression Inventory</p></def></def-item><def-item><term>KHP:</term><def><p>Korean Herbal Pharmacopoeia</p></def></def-item><def-item><term>KP:</term><def><p>Korean Pharmacopoeia</p></def></def-item><def-item><term>MD:</term><def><p>Meniere's disease</p></def></def-item><def-item><term>MVS:</term><def><p>Mean vertigo score</p></def></def-item><def-item><term>PRO:</term><def><p>Patient-rated outcome</p></def></def-item><def-item><term>QALY:</term><def><p>Quality-adjusted life year</p></def></def-item><def-item><term>QBYY-Q:</term><def><p>Qi blood yin yang-deficiency questionnaire</p></def></def-item><def-item><term>QoL:</term><def><p>Quality of life</p></def></def-item><def-item><term>RCT:</term><def><p>Randomized controlled trial</p></def></def-item><def-item><term>SPIRIT:</term><def><p>Standard Protocol Items: Recommendations for Interventional Trials</p></def></def-item><def-item><term>STAI:</term><def><p>State-Trait Anxiety Inventory</p></def></def-item><def-item><term>TKM:</term><def><p>Traditional Korean Medicine</p></def></def-item><def-item><term>VAS:</term><def><p>Visual analogue scale.</p></def></def-item></def-list></glossary><sec><title>Conflicts of Interest</title><p>The authors declare that there are no conflicts of interest regarding the publication of this article.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerber</surname><given-names>K. A.</given-names></name><name><surname>Baloh</surname><given-names>R. W.</given-names></name></person-group><article-title>The evaluation of a patient with dizziness</article-title><source><italic>Neurology: Clinical Practice</italic></source><year>2011</year><volume>1</volume><issue>1</issue><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="other">2-s2.0-84872298303</pub-id><pub-id pub-id-type="doi">10.1212/CPJ.0b013e31823d07b6</pub-id><pub-id pub-id-type="pmid">23634356</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D. K.</given-names></name></person-group><article-title xml:lang="ko">Clinical understanding to dizziness in the elderly</article-title><source><italic>Korean Journal of Clinical Geriatrics</italic></source><year>2014</year><volume>15</volume><issue>2</issue><fpage>45</fpage><lpage>55</lpage></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K. K.</given-names></name></person-group><article-title xml:lang="ko">Psychogenic dizziness for psychiatrists in Korea</article-title><source><italic>Korean Journal of Psychosomatic Medicine</italic></source><year>2016</year><volume>24</volume><issue>1</issue><fpage>9</fpage><lpage>19</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>S. Y.</given-names></name><name><surname>Hong</surname><given-names>S. K.</given-names></name></person-group><article-title xml:lang="ko">Evaluation and treatment of Meniere&#x02019;s disease</article-title><source><italic>Research in Vestibular Science</italic></source><year>2012</year><volume>11</volume><issue>Supplement 1</issue><fpage>4</fpage><lpage>8</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroenke</surname><given-names>K.</given-names></name><name><surname>Lucas</surname><given-names>C. A.</given-names></name><name><surname>Rosenberg</surname><given-names>M. L.</given-names></name><etal/></person-group><article-title>Causes of persistent dizziness: A prospective study of 100 patients in ambulatory care</article-title><source><italic>Annals of Internal Medicine</italic></source><year>1992</year><volume>117</volume><issue>11</issue><fpage>898</fpage><lpage>904</lpage><pub-id pub-id-type="other">2-s2.0-0026466116</pub-id><pub-id pub-id-type="doi">10.7326/0003-4819-117-11-898</pub-id><pub-id pub-id-type="pmid">1443950</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>S. Y.</given-names></name></person-group><article-title xml:lang="ko">Diagnosis and treatment of chronic dizziness</article-title><source><italic>Research in Vestibular Science</italic></source><year>2010</year><volume>9</volume><fpage>65</fpage><lpage>71</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="book"><source><italic>Review Assessment Service, Healthcare Bigdata Hub, Wonju: Health Insurance Review Assessment Service (Republic of Korea</italic></source><year>2017</year><publisher-loc>Wonju</publisher-loc><publisher-name>Health Insurance</publisher-name></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokolova</surname><given-names>L.</given-names></name><name><surname>Hoerr</surname><given-names>R.</given-names></name><name><surname>Mishchenko</surname><given-names>T.</given-names></name></person-group><article-title>Treatment of vertigo: a randomized, double-blind trial comparing efficacy and safety of ginkgo biloba extract EGb 761 and betahistine</article-title><source><italic>International Journal of Otolaryngology</italic></source><year>2014</year><volume>2014</volume><fpage>6</fpage><pub-id pub-id-type="publisher-id">682439</pub-id><pub-id pub-id-type="doi">10.1155/2014/682439</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>J. M.</given-names></name><name><surname>Eom</surname><given-names>T. M.</given-names></name><name><surname>Choi</surname><given-names>K. E.</given-names></name></person-group><article-title xml:lang="ko">Study of the patients with dizziness who visited the Korean medicine hospital</article-title><source><italic>Korean Journal of Oriental Physiology Pathology</italic></source><year>2015</year><volume>29</volume><issue>5</issue><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.15188/kjopp.2015.10.29.5.378</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>J.</given-names></name></person-group><source><italic>Dongeuibogam</italic></source><year>2014</year><publisher-loc>Seoul, South Korea</publisher-loc><publisher-name>Namsandang</publisher-name></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. H.</given-names></name><name><surname>Jo</surname><given-names>D. C.</given-names></name><name><surname>Kim</surname><given-names>C. G.</given-names></name><etal/></person-group><article-title xml:lang="ko">A literature review of effectiveness on the Gongjin-dan (Gongchen-dan)</article-title><source><italic>Journal of Korean Medicine Rehabilitation</italic></source><year>2013</year><volume>23</volume><issue>3</issue><fpage>69</fpage><lpage>78</lpage></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>E.</given-names></name><name><surname>Her</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>J. B.</given-names></name><etal/></person-group><article-title>The multi-herbal medicine Gongjin-dan enhances memory and learning tasks via NGF regulation</article-title><source><italic>Neuroscience Letters</italic></source><year>2009</year><volume>466</volume><issue>3</issue><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="other">2-s2.0-70350396592</pub-id><pub-id pub-id-type="doi">10.1016/j.neulet.2009.09.033</pub-id><pub-id pub-id-type="pmid">19788912</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.-S.</given-names></name><name><surname>Hong</surname><given-names>S.-S.</given-names></name><name><surname>Kim</surname><given-names>H.-G.</given-names></name><etal/></person-group><article-title>Gongjin-Dan enhances hippocampal memory in a mouse model of scopolamine-induced amnesia</article-title><source><italic>PLoS ONE</italic></source><year>2016</year><volume>11</volume><issue>8</issue><pub-id pub-id-type="other">2-s2.0-84983035878</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0159823</pub-id><pub-id pub-id-type="publisher-id">e0159823</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S.-S.</given-names></name><name><surname>Lee</surname><given-names>J.-Y.</given-names></name><name><surname>Lee</surname><given-names>J.-S.</given-names></name><etal/></person-group><article-title>The traditional drug Gongjin-Dan ameliorates chronic fatigue in a forced-stress mouse exercise model</article-title><source><italic>Journal of Ethnopharmacology</italic></source><year>2015</year><volume>168</volume><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="other">2-s2.0-84928496504</pub-id><pub-id pub-id-type="doi">10.1016/j.jep.2015.04.001</pub-id><pub-id pub-id-type="pmid">25865680</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>K. H.</given-names></name><name><surname>Park</surname><given-names>C. S.</given-names></name></person-group><article-title xml:lang="ko">An analysis of the Gongjindan`s ingredients and its efficacy on anti-oxidation</article-title><source><italic>The Korean Journal of Herbology</italic></source><year>2007</year><volume>22</volume><issue>2</issue><fpage>51</fpage><lpage>63</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunwoo</surname><given-names>Y. Y.</given-names></name><name><surname>Park</surname><given-names>S. I.</given-names></name><name><surname>Chung</surname><given-names>Y. A.</given-names></name></person-group><article-title>A pilot study for the neuroprotective effect of Gongjin-dan on transient middle cerebral artery occlusion-induced ischemic rat brain</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2012</year><volume>2012</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1155/2012/682720</pub-id><pub-id pub-id-type="publisher-id">682720</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>S. M.</given-names></name><name><surname>Chung</surname><given-names>D. K.</given-names></name></person-group><article-title xml:lang="ko">The effects of KongJin-dan (KJD) on the Alzheimer's disease model induced by CT105</article-title><source><italic>Journal of Oriental Neuropsychiatry</italic></source><year>2004</year><volume>15</volume><issue>2</issue><fpage>103</fpage><lpage>118</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y. H.</given-names></name><name><surname>Bae</surname><given-names>M. J.</given-names></name></person-group><article-title xml:lang="ko">The effect of Gongjindan on the lipid metabolism in rats fed high fat-diet</article-title><source><italic>The Journal of East-West Medicines</italic></source><year>1989</year><volume>14</volume><issue>2</issue><fpage>61</fpage><lpage>78</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>H. C.</given-names></name><name><surname>Jang</surname><given-names>H. J.</given-names></name><name><surname>Sung</surname><given-names>W. Y.</given-names></name><name><surname>Lee</surname><given-names>S. H.</given-names></name><name><surname>Son</surname><given-names>J. H.</given-names></name><name><surname>Han</surname><given-names>S. H.</given-names></name></person-group><article-title xml:lang="ko">A study of Gongjin-dan in patients with mild dementia of Alzheimer type</article-title><source><italic>Journal of Oriental Neuropsychiatry</italic></source><year>2004</year><volume>15</volume><issue>2</issue><fpage>141</fpage><lpage>148</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D. S.</given-names></name><name><surname>Kim</surname><given-names>D. W.</given-names></name></person-group><article-title xml:lang="ko">A effect of Gongchen-dan to anemia</article-title><source><italic>Journal of Kyungwon University Korean Medicine Institution</italic></source><year>2004</year><volume>7</volume><fpage>97</fpage><lpage>107</lpage></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname><given-names>M. J.</given-names></name><name><surname>Im</surname><given-names>H.-J.</given-names></name><name><surname>Kim</surname><given-names>Y.-E.</given-names></name><name><surname>Ku</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>J.-H.</given-names></name><name><surname>Son</surname><given-names>C.-G.</given-names></name></person-group><article-title>Evaluation of the anti-fatigue effects of a traditional herbal drug, Gongjin-dan, under insufficient sleep conditions: Study protocol for a randomised controlled trial</article-title><source><italic>Trials</italic></source><year>2016</year><volume>17</volume><issue>1, article no. 418</issue><pub-id pub-id-type="other">2-s2.0-84983337838</pub-id><pub-id pub-id-type="doi">10.1186/s13063-016-1542-7</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>A. W.</given-names></name><name><surname>Tetzlaff</surname><given-names>J. M.</given-names></name><name><surname>Altman</surname><given-names>D. G.</given-names></name><etal/></person-group><article-title>SPIRIT 2013 statement: defining standard protocol items for clinical trials</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2013</year><volume>158</volume><issue>3</issue><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-158-3-201302050-00583</pub-id><pub-id pub-id-type="other">2-s2.0-84872075614</pub-id><pub-id pub-id-type="pmid">23295957</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnier</surname><given-names>J. J.</given-names></name><name><surname>Boon</surname><given-names>H.</given-names></name><name><surname>Rochon</surname><given-names>P.</given-names></name><name><surname>Moher</surname><given-names>D.</given-names></name><name><surname>Barnes</surname><given-names>J.</given-names></name><name><surname>Bombardier</surname><given-names>C.</given-names></name></person-group><article-title>Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2006</year><volume>144</volume><issue>5</issue><fpage>364</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-144-5-200603070-00013</pub-id><pub-id pub-id-type="other">2-s2.0-33644884271</pub-id><pub-id pub-id-type="pmid">16520478</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>C.-Z.</given-names></name><name><surname>Shi</surname><given-names>G.-X.</given-names></name><etal/></person-group><article-title>Efficacy and safety of acupuncture for chronic dizziness: Study protocol for a randomized controlled trial</article-title><source><italic>Trials</italic></source><year>2013</year><volume>14</volume><issue>1, article no. 429</issue><pub-id pub-id-type="other">2-s2.0-84889981384</pub-id><pub-id pub-id-type="doi">10.1186/1745-6215-14-429</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="book"><collab>Association of department of pathology in Korea medicine</collab><source><italic>Pathology in Korean Medicine</italic></source><year>1998</year><publisher-loc>Seoul, Korea</publisher-loc><publisher-name>Iljungsa</publisher-name></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>G. P.</given-names></name><name><surname>Newman</surname><given-names>C. W.</given-names></name></person-group><article-title>The development of the Dizziness Handicap Inventory</article-title><source><italic>JAMA Otolaryngology&#x02013;Head &#x00026; Neck Surgery</italic></source><year>1990</year><volume>116</volume><issue>4</issue><fpage>424</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1001/archotol.1990.01870040046011</pub-id><pub-id pub-id-type="other">2-s2.0-0025275207</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>G. C.</given-names></name><name><surname>Lee</surname><given-names>E. J.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name><etal/></person-group><article-title xml:lang="ko">The study of standardization for a Korean adaptation of self-report measures of dizziness</article-title><source><italic>Journal of the Korean Balance Society</italic></source><year>2004</year><volume>3</volume><issue>2</issue><fpage>307</fpage><lpage>325</lpage></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novotn&#x000fd;</surname><given-names>M.</given-names></name><name><surname>Kost&#x00155;ica</surname><given-names>R.</given-names></name><name><surname>C&#x000ed;rek</surname><given-names>Z.</given-names></name></person-group><article-title>The efficacy of Arlevert therapy for vertigo and tinnitus</article-title><source><italic>International Tinnitus Journal</italic></source><year>1999</year><volume>5</volume><issue>1</issue><fpage>60</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">10753423</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novotn&#x000fd;</surname><given-names>M.</given-names></name><name><surname>Kost&#x00159;ica</surname><given-names>R.</given-names></name></person-group><article-title>Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Meniere's disease: a randomized, double-blind, parallel group clinical study</article-title><source><italic>International Tinnitus Journal</italic></source><year>2002</year><volume>8</volume><issue>2</issue><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">14763223</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholtz</surname><given-names>A. W.</given-names></name><name><surname>Schwarz</surname><given-names>M.</given-names></name><name><surname>Baumann</surname><given-names>W.</given-names></name><name><surname>Kleinfeldt</surname><given-names>D.</given-names></name><name><surname>Scholtz</surname><given-names>H.-J.</given-names></name></person-group><article-title>Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: A double-blind, randomized, parallel-group clinical study</article-title><source><italic>Clinical Therapeutics</italic></source><year>2004</year><volume>26</volume><issue>6</issue><fpage>866</fpage><lpage>877</lpage><pub-id pub-id-type="other">2-s2.0-3242674465</pub-id><pub-id pub-id-type="doi">10.1016/S0149-2918(04)90130-0</pub-id><pub-id pub-id-type="pmid">15262457</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirek</surname><given-names>Z.</given-names></name><name><surname>Schwarz</surname><given-names>M.</given-names></name><name><surname>Baumann</surname><given-names>W.</given-names></name><name><surname>Novotny</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy and tolerability of a fixed combination of cinnarizine and dimenhydrinate versus betahistine in the treatment of otogenic vertigo: A double-blind, randomised clinical study</article-title><source><italic>Clinical Drug Investigation</italic></source><year>2005</year><volume>25</volume><issue>6</issue><fpage>377</fpage><lpage>389</lpage><pub-id pub-id-type="other">2-s2.0-22544467782</pub-id><pub-id pub-id-type="doi">10.2165/00044011-200525060-00003</pub-id><pub-id pub-id-type="pmid">17532678</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pytel</surname><given-names>J.</given-names></name><name><surname>Nagy</surname><given-names>G.</given-names></name><name><surname>T&#x000f3;th</surname><given-names>A.</given-names></name><name><surname>Spellenberg</surname><given-names>S.</given-names></name><name><surname>Schwarz</surname><given-names>M.</given-names></name><name><surname>R&#x000e9;passy</surname><given-names>G.</given-names></name></person-group><article-title>Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: A 4-week, randomized, double-blind, active- and placebo-controlled, parallel-group, outpatient study</article-title><source><italic>Clinical Therapeutics</italic></source><year>2007</year><volume>29</volume><issue>1</issue><fpage>84</fpage><lpage>98</lpage><pub-id pub-id-type="other">2-s2.0-33947112957</pub-id><pub-id pub-id-type="doi">10.1016/j.clinthera.2007.01.010</pub-id><pub-id pub-id-type="pmid">17379049</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>A.</given-names></name><name><surname>Sejna</surname><given-names>I.</given-names></name><name><surname>Stefflova</surname><given-names>B.</given-names></name><name><surname>Schwarz</surname><given-names>M.</given-names></name><name><surname>Baumann</surname><given-names>W.</given-names></name></person-group><article-title>A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders: A randomized, reference-controlled clinical study</article-title><source><italic>Clinical Drug Investigation</italic></source><year>2008</year><volume>28</volume><issue>2</issue><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="other">2-s2.0-38949151948</pub-id><pub-id pub-id-type="doi">10.2165/00044011-200828020-00003</pub-id><pub-id pub-id-type="pmid">18211117</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>V.</given-names></name><name><surname>Fischer</surname><given-names>B.</given-names></name><name><surname>Schwarz</surname><given-names>M.</given-names></name><name><surname>Baumann</surname><given-names>W.</given-names></name><name><surname>Preibisch-Effenberger</surname><given-names>R.</given-names></name></person-group><article-title>Treatment of vertebrobasilar insufficiency-associated vertigo with a fixed combination of cinnarizine and dimenhydrinate</article-title><source><italic>The International Tinnitus Journal</italic></source><year>2008</year><volume>14</volume><issue>1</issue><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">18616088</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>A.</given-names></name><name><surname>Novotn&#x000fd;</surname><given-names>M.</given-names></name><name><surname>Shotekov</surname><given-names>P. M.</given-names></name><name><surname>Cirek</surname><given-names>Z.</given-names></name><name><surname>Bognar-Steinberg</surname><given-names>I.</given-names></name><name><surname>Baumann</surname><given-names>W.</given-names></name></person-group><article-title>Comparison of cinnarizinedimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins: A randomized, double-blind, active-controlled, multicentre study</article-title><source><italic>Clinical Drug Investigation</italic></source><year>2011</year><volume>31</volume><issue>6</issue><fpage>371</fpage><lpage>383</lpage><pub-id pub-id-type="other">2-s2.0-79955582807</pub-id><pub-id pub-id-type="doi">10.2165/11588920-000000000-00000</pub-id><pub-id pub-id-type="pmid">21401214</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toupet</surname><given-names>M.</given-names></name><name><surname>Ferrary</surname><given-names>E.</given-names></name><name><surname>Grayeli</surname><given-names>A. B.</given-names></name></person-group><article-title>Visual analog scale to assess vertigo and dizziness after repositioning maneuvers for benign paroxysmal positional vertigo</article-title><source><italic>Journal of Vestibular Research</italic></source><year>2011</year><volume>21</volume><issue>4</issue><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">21846956</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>C. W.</given-names></name><name><surname>Lee</surname><given-names>T. C.</given-names></name><name><surname>Hsu</surname><given-names>P. C.</given-names></name><etal/></person-group><article-title>Efficacy and safety of acupuncture for dizziness and vertigo in emergency department: a pilot cohort study</article-title><source><italic>BMC Complementary and Alternative Medicine</italic></source><year>2015</year><volume>15, article 173</volume><pub-id pub-id-type="doi">10.1186/s12906-015-0704-6</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>S. A.</given-names></name><name><surname>Rivett</surname><given-names>D. A.</given-names></name><name><surname>Katekar</surname><given-names>M. G.</given-names></name><name><surname>Callister</surname><given-names>R.</given-names></name></person-group><article-title>Sustained natural apophyseal glides (SNAGs) are an effective treatment for cervicogenic dizziness</article-title><source><italic>Manual Therapy</italic></source><year>2008</year><volume>13</volume><issue>4</issue><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="other">2-s2.0-45249112550</pub-id><pub-id pub-id-type="doi">10.1016/j.math.2007.03.006</pub-id><pub-id pub-id-type="pmid">17951095</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>S. A.</given-names></name><name><surname>Rivett</surname><given-names>D. A.</given-names></name><name><surname>Katekar</surname><given-names>M. G.</given-names></name><name><surname>Callister</surname><given-names>R.</given-names></name></person-group><article-title>Efficacy of manual therapy treatments for people with cervicogenic dizziness and pain: Protocol of a randomised controlled trial</article-title><source><italic>BMC Musculoskeletal Disorders</italic></source><year>2012</year><volume>13, article no. 201</volume><pub-id pub-id-type="other">2-s2.0-84867569551</pub-id><pub-id pub-id-type="doi">10.1186/1471-2474-13-201</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>S. A.</given-names></name><name><surname>Rivett</surname><given-names>D. A.</given-names></name><name><surname>Katekar</surname><given-names>M. G.</given-names></name><name><surname>Callister</surname><given-names>R.</given-names></name></person-group><article-title>Comparison of mulligan sustained natural apophyseal glides and maitland mobilizations for treatment of cervicogenic dizziness: A randomized controlled trial</article-title><source><italic>Physical Therapy in Sport</italic></source><year>2014</year><volume>94</volume><issue>4</issue><fpage>466</fpage><lpage>476</lpage><pub-id pub-id-type="other">2-s2.0-84897437523</pub-id><pub-id pub-id-type="doi">10.2522/ptj.20120483</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>S. A.</given-names></name><name><surname>Callister</surname><given-names>R.</given-names></name><name><surname>Snodgrass</surname><given-names>S. J.</given-names></name><name><surname>Katekar</surname><given-names>M. G.</given-names></name><name><surname>Rivett</surname><given-names>D. A.</given-names></name></person-group><article-title>Manual therapy for cervicogenic dizziness: Long-term outcomes of a randomised trial</article-title><source><italic>Manual Therapy</italic></source><year>2015</year><volume>20</volume><issue>1</issue><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="other">2-s2.0-84920195094</pub-id><pub-id pub-id-type="doi">10.1016/j.math.2014.08.003</pub-id><pub-id pub-id-type="pmid">25220110</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>K.</given-names></name><name><surname>Wood-Dauphinee</surname><given-names>S.</given-names></name><name><surname>Williams</surname><given-names>J. I.</given-names></name><name><surname>Gayton</surname><given-names>D.</given-names></name></person-group><article-title>Measuring balance in the elderly: preliminary development of an instrument</article-title><source><italic>Physiotherapy Canada</italic></source><year>1989</year><volume>41</volume><issue>6</issue><fpage>304</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.3138/ptc.41.6.304</pub-id><pub-id pub-id-type="other">2-s2.0-0024801297</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>K.</given-names></name><name><surname>Wood-Dauphinee</surname><given-names>S.</given-names></name><name><surname>Williams</surname><given-names>J. I.</given-names></name></person-group><article-title>The balance scale: reliability assessment with elderly residents and patients with an acute stroke</article-title><source><italic>Scandinavian Journal of Rehabilitation Medicine</italic></source><year>1995</year><volume>27</volume><issue>1</issue><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">7792547</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>K. O.</given-names></name><name><surname>Wood-Dauphinee</surname><given-names>S. L.</given-names></name><name><surname>Williams</surname><given-names>J. I.</given-names></name><name><surname>Maki</surname><given-names>B.</given-names></name></person-group><article-title>Measuring balance in the elderly: validation of an instrument</article-title><source><italic>Canadian Journal of Public Health</italic></source><year>1992</year><volume>83</volume><issue>supplement 2</issue><fpage>S7</fpage><lpage>S11</lpage><pub-id pub-id-type="pmid">1468055</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorbahn</surname><given-names>L. D. B.</given-names></name><name><surname>Newton</surname><given-names>R. A.</given-names></name></person-group><article-title>Use of the Berg balance test to predict falls in elderly persons</article-title><source><italic>Physical Therapy in Sport</italic></source><year>1996</year><volume>76</volume><issue>6</issue><fpage>576</fpage><lpage>585</lpage><pub-id pub-id-type="other">2-s2.0-0029994389</pub-id><pub-id pub-id-type="doi">10.1093/ptj/76.6.576</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>H. Y.</given-names></name><name><surname>Park</surname><given-names>J. H.</given-names></name><name><surname>Shim</surname><given-names>J. J.</given-names></name><name><surname>Kim</surname><given-names>M. J.</given-names></name><name><surname>Hwang</surname><given-names>M. R.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name></person-group><article-title>Reliability test of Korean version of berg balance scale</article-title><source><italic>Annals of Rehabilitation Medicine</italic></source><year>2006</year><volume>30</volume><issue>6</issue><fpage>611</fpage><lpage>618</lpage></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewlett</surname><given-names>S.</given-names></name><name><surname>Dures</surname><given-names>E.</given-names></name><name><surname>Almeida</surname><given-names>C.</given-names></name></person-group><article-title>Measures of fatigue: Bristol rheumatoid arthritis fatigue multi-dimensional questionnaire (BRAF MDQ), Bristol rheumatoid arthritis fatigue numerical rating scales (BRAF NRS) for severity, effect, and coping, Chalder fatigue questionnaire (CFQ), checklist individual strength (CIS20R and CIS8R), fatigue severity scale (FSS), functional assessment chronic illness therapy (Fatigue) (FACIT-F), multi-dimensional assessment of fatigue (MAF), multi-dimensional fatigue inventory (MFI), pediatric quality of life (PedsQL) multi-dimensional fatigue scale, profile of fatigue (ProF), short form 36 vitality subscale (SF-36 VT), and visual analog scales (VAS)</article-title><source><italic>Arthritis Care and Research</italic></source><year>2011</year><volume>63</volume><issue>supplement 11</issue><fpage>S263</fpage><lpage>S286</lpage><pub-id pub-id-type="pmid">22588750</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamper</surname><given-names>S. J.</given-names></name><name><surname>Ostelo</surname><given-names>R. W. J. G.</given-names></name><name><surname>Knol</surname><given-names>D. L.</given-names></name><name><surname>Maher</surname><given-names>C. G.</given-names></name><name><surname>de Vet</surname><given-names>H. C. W.</given-names></name><name><surname>Hancock</surname><given-names>M. J.</given-names></name></person-group><article-title>Global Perceived Effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status</article-title><source><italic>Journal of Clinical Epidemiology</italic></source><year>2010</year><volume>63</volume><issue>7</issue><fpage>760</fpage><lpage>e1</lpage><pub-id pub-id-type="other">2-s2.0-77952421365</pub-id><pub-id pub-id-type="doi">10.1016/j.jclinepi.2009.09.009</pub-id><pub-id pub-id-type="pmid">20056385</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staab</surname><given-names>J. P.</given-names></name><name><surname>Ruckenstein</surname><given-names>M. J.</given-names></name></person-group><article-title>Chronic dizziness and anxiety: Effect of course of illness on treatment outcome</article-title><source><italic>Archives of Otolaryngology&#x02014;Head and Neck Surgery</italic></source><year>2005</year><volume>131</volume><issue>8</issue><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="other">2-s2.0-23944520814</pub-id><pub-id pub-id-type="doi">10.1001/archotol.131.8.675</pub-id><pub-id pub-id-type="pmid">16103297</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>M. K.</given-names></name><name><surname>Lee</surname><given-names>Y. H.</given-names></name><name><surname>Jung</surname><given-names>H. Y.</given-names></name><etal/></person-group><article-title xml:lang="ko">A standardization study of beck depression inventory II - Korean version (K-BDI): validity</article-title><source><italic>The Korean Journal of Psychopathology</italic></source><year>1995</year><volume>4</volume><issue>1</issue><fpage>96</fpage><lpage>104</lpage></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>M. K.</given-names></name><name><surname>Lee</surname><given-names>Y. H.</given-names></name><name><surname>Park</surname><given-names>S. H.</given-names></name><etal/></person-group><article-title xml:lang="ko">A standardization study of beck depression inventory I - Korean version (K-BDI): reliability and factor analysis</article-title><source><italic>The Korean Journal of Psychopathology</italic></source><year>1995</year><volume>4</volume><issue>1</issue><fpage>77</fpage><lpage>95</lpage></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julian</surname><given-names>L. J.</given-names></name></person-group><article-title>Measures of anxiety</article-title><source><italic>Arthritis Care and Research</italic></source><year>2011</year><volume>63</volume><issue>supplement S11</issue><fpage>S467</fpage><lpage>S472</lpage><pub-id pub-id-type="doi">10.1002/acr.20561</pub-id><pub-id pub-id-type="pmid">22588767</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Choi</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name></person-group><article-title xml:lang="ko">Development of questionnaires for differentiation of q&#x000ec;-x&#x0016b;, xu&#x000e8;-x&#x0016b;, yang-x&#x0016b;, y&#x0012b;n-x&#x0016b; analysis</article-title><source><italic>The Journal of Internal Korean Medicine</italic></source><year>2008</year><volume>29</volume><issue>4</issue><fpage>856</fpage><lpage>870</lpage></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Ku</surname><given-names>B. C.</given-names></name><name><surname>Kim</surname><given-names>J. E.</given-names></name><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>Kim</surname><given-names>K. H.</given-names></name></person-group><article-title xml:lang="ko">Study on reliability and validity of the &#x0201c;qi blood yin yang deficiency questionnaire&#x0201d;</article-title><source><italic>Korean Journal of Oriental Physiology &#x00026; Pathology</italic></source><year>2014</year><volume>28</volume><issue>3</issue><fpage>346</fpage><lpage>354</lpage></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Ku</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>K. H.</given-names></name></person-group><article-title>Validation of the qi blood yin yang deficiency questionnaire on chronic fatigue</article-title><source><italic>Chinese Medicine</italic></source><year>2016</year><volume>11</volume><fpage>p. 24</fpage><pub-id pub-id-type="pmid">27141228</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>H.</given-names></name><name><surname>Ni</surname><given-names>L.</given-names></name><name><surname>Davis</surname><given-names>C. E.</given-names></name></person-group><article-title>Assessment of blinding in clinical trials</article-title><source><italic>Controlled Clinical Trials</italic></source><year>2004</year><volume>25</volume><issue>2</issue><fpage>143</fpage><lpage>156</lpage><pub-id pub-id-type="other">2-s2.0-1542291119</pub-id><pub-id pub-id-type="doi">10.1016/j.cct.2003.10.016</pub-id><pub-id pub-id-type="pmid">15020033</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>T. H.</given-names></name></person-group><source xml:lang="ko"><italic>Validity and reliability evaluation for EQ-5D in the general population of South Korea</italic></source><year>2012</year><publisher-loc>Ulsan, South Korea</publisher-loc><publisher-name>College of Medicine, Ulsan University</publisher-name></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.</given-names></name></person-group><source xml:lang="zh"><italic>Clinical research on traditional acupuncture manipulation combined with the moxibustion on BaiHui of Meniere&#x02019;s disease</italic></source><year>2011</year><publisher-loc>Guangdong Sheng, China</publisher-loc><publisher-name>Guangzhou University of Chinese Medicine</publisher-name></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study flowchart. BBS, Berg Balance Scale; BI, Blinding Index; CNS, central nervous system; DHI, Dizziness Handicap Inventory; EQ-5D, EuroQoL five dimensions' questionnaire; FSS, Fatigue Severity Scale; GJD,<italic> Gongjindan</italic>; GPE, Global perceived effect; K-BDI, Korean version of Beck's Depression Inventory; MVS, mean vertigo scale; QBYY-Q, qi blood yin yang-deficiency questionnaire; STAI, State-Trait Anxiety Inventory; VAS, visual analogue scale; wks, weeks; yr, year.</p></caption><graphic xlink:href="ECAM2017-4363716.001"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Study timetable.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Screening</th><th align="center" rowspan="1" colspan="1">Randomization</th><th colspan="4" align="center" rowspan="1">Treatment</th><th colspan="3" align="center" rowspan="1">Follow-up</th></tr><tr><th align="left" rowspan="1" colspan="1">Visits</th><th align="center" rowspan="1" colspan="1">V1</th><th align="center" rowspan="1" colspan="1">V2</th><th align="center" rowspan="1" colspan="1">
<italic>V3</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>V4</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>V5</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>V6</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>V7</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>V8</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>V9</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">Timepoint</th><th align="center" rowspan="1" colspan="1">
<italic>Within 14&#x02009;D</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>Day 0</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>14&#x02009;D &#x000b1; 3&#x02009;D</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>28&#x02009;D &#x000b1; 3&#x02009;D</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>42&#x02009;D &#x000b1; 3&#x02009;D</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>56&#x02009;D &#x000b1; 3&#x02009;D</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>4&#x02009;M &#x000b1; 1&#x02009;W</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>8&#x02009;M &#x000b1; 1&#x02009;W</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>12&#x02009;M &#x000b1; 1&#x02009;W</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Enrollment:</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Informed consent</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Demographics</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Vital sign</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Electrocardiography</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Lab test</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Medical history</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Concomitant medication</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Pregnancy test</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CNS examination</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Nystagmus examination</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Eligibility assessment</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Random allocation</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Interventions:</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>GJD (1 pill/day)</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td colspan="4" align="center" rowspan="1">
<inline-graphic xlink:href="ECAM2017-4363716.tab1.i001.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Placebo (1 pill/day)</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td colspan="4" align="center" rowspan="1">
<inline-graphic xlink:href="ECAM2017-4363716.tab1.i002.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Assessments:</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>DHI</italic>
</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>MVS</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>VAS</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Frequency</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>BBS</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>FSS</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>GPE</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>K-BDI</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>STAI</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>QBYY-Q</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EQ-5D</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Cost information</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>New BI</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Adverse events</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x000d7;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr></tbody></table><table-wrap-foot><fn><p>BBS, Berg Balance Scale; BI, Blinding Index; D, day(s); DHI, Dizziness Handicap Inventory; EQ-5D, EuroQoL five dimensions' questionnaire; FSS, Fatigue Severity Scale; GJD, <italic>Gongjindan</italic>; GPE, global perceived effect; K-BDI, Korean version of Beck's Depression Inventory; M, month(s); MVS, mean vertigo scale; QBYY-Q, qi blood yin yang-deficiency questionnaire; STAI, State-Trait Anxiety Inventory; VAS, visual analogue scale; W, week(s).</p></fn></table-wrap-foot></table-wrap></floats-group></article>